Esperion Therapeutics (ESPR) Total Current Liabilities (2012 - 2026)

Esperion Therapeutics has reported Total Current Liabilities for 15 years, with the latest figure at $300.4 million in Q1 2026.

• For the quarter ending Q1 2026, Total Current Liabilities rose 10.85% year-over-year to $300.4 million; the trailing twelve-month figure through Mar 2026 stood at $300.4 million (up 10.85% YoY), and the FY2025 full-year result was $300.8 million, up 22.16% from the prior year.
• Total Current Liabilities for Q1 2026 stood at $300.4 million, roughly flat from $300.8 million in the prior quarter.
• The five-year high for Total Current Liabilities was $359.0 million in Q3 2025, with the low at $79.1 million in Q1 2022.
• Historically, Total Current Liabilities has averaged $183.2 million across 5 years, with a median of $164.5 million in 2024.
• Annual changes were most pronounced in 2022 — Total Current Liabilities fell 19.21% — and 2025, when it soared 116.45%.
• Esperion Therapeutics' Total Current Liabilities stood at $92.3 million in 2022, then surged by 69.24% to $156.2 million in 2023, then jumped by 57.62% to $246.2 million in 2024, then rose by 22.16% to $300.8 million in 2025, then retreated by 0.15% to $300.4 million in 2026.
• The last three Total Current Liabilities figures came in at $300.4 million (Q1 2026), $300.8 million (Q4 2025), and $359.0 million (Q3 2025), per Business Quant data.